Some Good and Bad Investment News for Biotech Companies
Let’s start with the good news first. A report issued by the National Capital Association and PricewaterhouseCoopers found that venture capital investment in biotechnology grew 22 percent in 2011. And, now the bad news; initial funding for biotechnology startups seeking investment hit a 16 year low last year. The consensus among financial analysts is that life science investors are increasingly focusing on later stage companies because they carry less clinical and regulatory risks as compared with early stage ones. Put simply, VCs, like everyone else, have become much more risk adverse and do not want to invest in companies that don’t have a minimum history of success.
According to the report, venture firms spent $4.73 billion on 446 biotechnology companies in 2011, the highest dollar amount since 2007. Approximately, 153 biotechnology and medical devices companies received their first round of funding last year.
Finally, the US Food and Drug Administration approved 30 drugs in 2011; 13 of which were developed in part by venture funding.
Until next time...
Good Luck and Good Job Hunting!!!!!!!!!!!!
The 
Despite dire predictions, the biotechnology industry appears to be weathering the recession better than most. According to a
